• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Defining the impact of individual sample variability on routine immunoassay of serum free light chains (sFLC) in multiple myeloma.定义个体样本变异对多发性骨髓瘤患者血清游离轻链(sFLC)常规免疫分析的影响。
Clin Exp Immunol. 2013 Feb;171(2):201-9. doi: 10.1111/cei.12011.
2
Robust Reference Intervals for Serum Kappa and Lambda Free Light Chains from a Multi Centre Study Population from Hyderabad, India: Myeloma Diagnostic Implications.来自印度海得拉巴多中心研究人群的血清κ和λ游离轻链的稳健参考区间:对骨髓瘤诊断的意义
Asian Pac J Cancer Prev. 2016;17(5):2605-10.
3
[Detection of serum free light chain and its clinical significance in nonsecretory multiple myeloma].非分泌型多发性骨髓瘤血清游离轻链的检测及其临床意义
Zhonghua Xue Ye Xue Za Zhi. 2008 Feb;29(2):113-6.
4
[Clinical significance of serum free light chain in patients with multiple myeloma].[血清游离轻链在多发性骨髓瘤患者中的临床意义]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Aug;21(4):930-5. doi: 10.7534/j.issn.1009-2137.2013.04.023.
5
[Test of Serum Free Light Chain and Its Clinical Significance in Light Chain Multiple Myeloma].血清游离轻链检测及其在轻链型多发性骨髓瘤中的临床意义
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Oct;23(5):1357-61. doi: 10.7534/j.issn.1009-2137.2015.05.025.
6
[The Value of sFLC and Serum Calcium in the Diagnosis and Prognosis of Multiple Myeloma Patients].[sFLC和血清钙在多发性骨髓瘤患者诊断及预后中的价值]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Jun;32(3):794-798. doi: 10.19746/j.cnki.issn.1009-2137.2024.03.021.
7
Serum free light chain analysis: persisting limitations with new kids on the block.血清游离轻链分析:新成员的持续局限性。
Clin Chem Lab Med. 2022 Jul 4;60(9):1440-1448. doi: 10.1515/cclm-2022-0347. Print 2022 Aug 26.
8
[Assessment of serum free light chain of patients with multiple myeloma and clinical significance thereof].[多发性骨髓瘤患者血清游离轻链的检测及其临床意义]
Zhonghua Yi Xue Za Zhi. 2007 Nov 27;87(44):3158-60.
9
Serum Free Light Chains in Common Variable Immunodeficiency Disorders: Role in Differential Diagnosis and Association With Clinical Phenotype.常见可变免疫缺陷病中的血清游离轻链:在鉴别诊断中的作用及与临床表型的关联。
Front Immunol. 2020 Mar 31;11:319. doi: 10.3389/fimmu.2020.00319. eCollection 2020.
10
Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.应使用血清游离轻链而非尿液标本评估轻链型多发性骨髓瘤的反应。
Blood. 2016 Dec 22;128(25):2941-2948. doi: 10.1182/blood-2016-07-726778. Epub 2016 Oct 11.

引用本文的文献

1
Performance Characteristics and Limitations of the Available Assays for the Detection and Quantitation of Monoclonal Free Light Chains and New Emerging Methodologies.用于检测和定量单克隆游离轻链的现有检测方法的性能特征与局限性以及新兴方法
Antibodies (Basel). 2024 Mar 11;13(1):19. doi: 10.3390/antib13010019.
2
Smoldering multiple myeloma: Reviewing the rationale for intervention.冒烟型多发性骨髓瘤:干预策略的探讨。
Leuk Lymphoma. 2022 Sep;63(9):2033-2040. doi: 10.1080/10428194.2022.2068008. Epub 2022 May 9.
3
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.解读多发性骨髓瘤临床试验数据:将研究结果转化至实际应用场景。
Blood Cancer J. 2018 Nov 9;8(11):109. doi: 10.1038/s41408-018-0141-0.
4
Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.在三项 PETHEMA/GEM 三期临床试验中,血清游离轻链比值和重轻链比值对多发性骨髓瘤的预后价值。
PLoS One. 2018 Sep 7;13(9):e0203392. doi: 10.1371/journal.pone.0203392. eCollection 2018.

本文引用的文献

1
Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies.血清蛋白电泳 M 峰、尿 M 峰和单克隆血清游离轻链定量的长期生物学变异:对监测单克隆丙种球蛋白病的意义。
Clin Chem. 2011 Dec;57(12):1687-92. doi: 10.1373/clinchem.2011.171314. Epub 2011 Oct 6.
2
Effect of sample dilution on serum free light chain concentration by immunonephelometric assay.免疫散射比浊法检测血清游离轻链时样本稀释对浓度的影响。
Clin Chim Acta. 2011 Sep 18;412(19-20):1798-804. doi: 10.1016/j.cca.2011.06.021. Epub 2011 Jun 29.
3
Guidelines for the diagnosis and management of multiple myeloma 2011.2011年多发性骨髓瘤诊断与管理指南
Br J Haematol. 2011 Jul;154(1):32-75. doi: 10.1111/j.1365-2141.2011.08573.x. Epub 2011 May 14.
4
Interlaboratory study of free monoclonal immunoglobulin light chain quantification.单克隆免疫球蛋白游离轻链定量的实验室间研究。
Clin Chem Lab Med. 2011 Jan;49(1):89-92. doi: 10.1515/CCLM.2011.019. Epub 2010 Oct 29.
5
Polyclonal free light chain of Ig may interfere with interpretation of monoclonal free light chain κ/λ ratio.免疫球蛋白的多克隆游离轻链可能会干扰单克隆游离轻链κ/λ比值的解读。
Ann Clin Lab Sci. 2010 Fall;40(4):348-53.
6
Comparison of serum immunofixation electrophoresis and free light chain assays in the detection of monoclonal gammopathies.血清免疫固定电泳与游离轻链检测在单克隆丙种球蛋白病检测中的比较。
Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):278-80. doi: 10.3816/CLML.2010.n.057.
7
Hook effect with lambda free light chain in serum free light chain assay.
Clin Chim Acta. 2010 Nov 11;411(21-22):1834-6. doi: 10.1016/j.cca.2010.07.027. Epub 2010 Jul 25.
8
Detection of serum free light chains: the problem with antigen excess.血清游离轻链检测:抗原过剩问题。
Clin Chem Lab Med. 2010 Oct;48(10):1419-22. doi: 10.1515/CCLM.2010.283. Epub 2010 Jul 13.
9
Questionable role of free light chain assay ratio to determine stringent complete remission in multiple myeloma patients.游离轻链检测比值在确定多发性骨髓瘤患者严格完全缓解中的可疑作用。
Blood. 2010 Apr 22;115(16):3413-4; author reply 3414-5. doi: 10.1182/blood-2010-01-261677.
10
Overestimation of serum kappa free light chain concentration by immunonephelometry.免疫比浊法对血清κ游离轻链浓度的高估
Clin Chem. 2010 Jul;56(7):1188-90. doi: 10.1373/clinchem.2010.143529. Epub 2010 Apr 22.

定义个体样本变异对多发性骨髓瘤患者血清游离轻链(sFLC)常规免疫分析的影响。

Defining the impact of individual sample variability on routine immunoassay of serum free light chains (sFLC) in multiple myeloma.

机构信息

Immunology Department, Northern General Hospital, Sheffield, UK.

出版信息

Clin Exp Immunol. 2013 Feb;171(2):201-9. doi: 10.1111/cei.12011.

DOI:10.1111/cei.12011
PMID:23286947
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3573291/
Abstract

Serum free light chain (sFLC) measurement has gained widespread acceptance and is incorporated into various diagnostic and response criteria. Non-linearity and antigen excess are the main causes of 'variability' in the measurement of sFLC using immunoassay, but the impact of these on measurement has been unclear. We performed a retrospective evaluation using a dilutional strategy to detect these phenomena. A total of 464 samples in 2009 and 373 samples in 2010 were analysed for sFLC. Non-linearity was detected in both high and apparently normal sFLC. Major non-linearity of more than twofold is common in high kappa (20·2%) and lambda (14·1%). It is less common in samples with apparently normal levels - kappa (6·4%) and lambda (9·5%). 9·4% of kappa and 15·5% of lambda showed antigen excess at screening dilutions. 34·4% of the samples had either non-linearity or antigen excess. We conclude that significant measurement variability is common in the measurement of sFLC. There is currently no reliable technique to detect non-linearity phenomena unless a serial dilution strategy is applied to every analysis. We recommend that laboratories routinely reporting sFLC results for clinical services need appropriate strategies for addressing these issues. Clinicians should be aware of these limitations in interpretation of sFLC assay for individual patients. Future guidelines should adopt action thresholds which are grounded firmly in test performance parameters.

摘要

血清游离轻链(sFLC)的检测已经得到了广泛的认可,并被纳入了各种诊断和反应标准。免疫测定法在检测 sFLC 时,由于非线性和抗原过剩是导致“可变性”的主要原因,但这些因素对检测的影响尚不清楚。我们使用稀释策略进行了回顾性评估,以检测这些现象。对 2009 年的 464 个样本和 2010 年的 373 个样本进行了 sFLC 分析。在高和明显正常的 sFLC 中均检测到非线性。高 κ(20.2%)和 λ(14.1%)的两倍以上的主要非线性很常见。在具有明显正常水平的样本中, κ(6.4%)和 λ(9.5%)的情况则较少见。在筛选稀释液中, κ(9.4%)和 λ(15.5%)的 9.4%显示出抗原过剩。有 34.4%的样本出现非线性或抗原过剩。我们的结论是,在 sFLC 的检测中,明显的测量可变性很常见。除非对每个分析应用连续稀释策略,否则目前没有可靠的技术来检测非线性现象。我们建议,为临床服务常规报告 sFLC 结果的实验室需要有适当的策略来解决这些问题。临床医生应注意在对个体患者的 sFLC 检测结果进行解释时存在这些局限性。未来的指南应采用牢固基于测试性能参数的行动阈值。